#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Intracranial calcification Stevens-Johnson syndrome Thrombotic microangiopathy Systemic mastocytosis Macular telangiectasia Testicular leiomyosarcoma Encephalopathy neonatal Prostate cancer Urea cycle disorder Autoimmune hepatitis Vaginal cancer Advanced systemic mastocytosis Inborn error of metabolism Sarcoidosis Spinal cord injury cervical More trials…

    Learn about Rare Diseases

    Lymphangiosarcoma – Diagnostics Chondrosarcoma – Basic Information CADASIL Antithrombin III deficiency – Treatment Sjogren’s syndrome – Life with Disease Haemophagocytic lymphohistiocytosis – Basic Information Marginal zone lymphoma refractory – Life with Disease Nephroblastoma – Life with Disease Adrenogenital syndrome – Basic Information Wiskott-Aldrich syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tegoprubart Botaretigene Sparoparvovec Infigratinib Tipiracil Hydrochloride Cpft Trifluoroacetate Imifoplatin Rbd4059 SONLICROMANOL HYDROCHLORIDE Blood And Related Products NVG-2089 Regn7257 Tas3351 Dried Ferrous Sulfate Pemetrexed Disodium Sym024 Bms-986288 Alternaria Alternata (402) Colecalciferol Daptomycin Fosphenytoin Sodium More therapies…

    Learn about Your Condition

    Hypertonic bladder Malabsorption Ataxia telangiectasia Knee arthroplasty Uterine leiomyoma Thrombocytopenia Major depression Mechanical ventilation Nicotine dependence Dry mouth Coeliac disease Dementia Alzheimer's type Magnetic resonance imaging Fibrous dysplasia of bone Thrombosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Transitional cell carcinoma metastatic

  • Safety and Antitumor Activity of PF-08634404 Alone or with Enfortumab Vedotin in Adults with Locally Advanced or Metastatic Urothelial Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Enfortumab Vedotin
    The Netherlands Spain

  • Phase 1/2 Evaluation of Zilovertamab Vedotin in PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • SKB410
    • Zilovertamab Vedotin
    • Pembrolizumab
    Denmark Italy The Netherlands Spain

  • Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine
    Austria Belgium Czechia France Germany Ireland +5

  • Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Avelumab
    Italy

  • Study of Livmoniplimab and Budigalimab Compared to Chemotherapy for Adults with Advanced Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    • Transitional cell carcinoma
    Investigated Drugs:
    • Livmoniplimab
    • Budigalimab
    • Docetaxel
    Belgium France Poland Spain

  • Study on Nivolumab and Ipilimumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma metastatic
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!